A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 361 participants.

Also called NCT05362110

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 361 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05362110
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05362110. Randomized; double masking; primary purpose treatment. Start 2022-05-16 (actual); primary completion 2023-06-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
Acronym
HM_APOLLO
Condition
Hypertension
Intervention (Drug)
HCP1803-3
Intervention (Drug)
RLD2002
Intervention (Drug)
HPP2003-3
Intervention (Drug)
HPP2004
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct05362110
Content hash
e3484d4cb5e23a1901dea173e77bcf6b164f2f470826f6b3040224e9d57bf553